CASI Pharmaceuticals, Inc. (CASI)

NASDAQ: CASI · IEX Real-Time Price · USD
5.59
0.00 (0.00%)
At close: Dec 1, 2023, 4:00 PM
5.38
-0.21 (-3.76%)
After-hours: Dec 1, 2023, 5:20 PM EST
0.00%
Market Cap 74.47M
Revenue (ttm) 42.26M
Net Income (ttm) -40.42M
Shares Out 13.32M
EPS (ttm) -3.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 22,379
Open 5.56
Previous Close 5.59
Day's Range 5.38 - 5.72
52-Week Range 1.45 - 5.94
Beta 0.16
Analysts Strong Buy
Price Target 12.00 (+114.67%)
Earnings Date Nov 14, 2023

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 1996
Employees 224
Stock Exchange NASDAQ
Ticker Symbol CASI
Full Company Profile

Financial Performance

In 2022, CASI's revenue was $43.11 million, an increase of 42.89% compared to the previous year's $30.17 million. Losses were -$41.01 million, 11.9% more than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for CASI stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target
$12.0
(114.67% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

BEIJING , Nov. 14, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical prod...

20 days ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

BEIJING , Nov. 8, 2023 /PRNewswire/ -- CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical produc...

26 days ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

BEIJING , Aug. 11, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical prod...

4 months ago - PRNewsWire

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

BEIJING , Aug. 1, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical produ...

4 months ago - PRNewsWire

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339

BEIJING , July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical prod...

4 months ago - PRNewsWire

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

SAN FRANCISCO--(BUSINESS WIRE)--Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the co...

4 months ago - Business Wire

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

BEIJING , May 17, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing innovative therapeut...

7 months ago - PRNewsWire

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

BEIJING , April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeut...

7 months ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

BEIJING , April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

7 months ago - PRNewsWire

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

BEIJING , March 21, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing innovative therapeut...

9 months ago - PRNewsWire

Casi Pharmaceuticals to run clinical trial for multiple myeloma drug in China

Shares of Casi Pharmaceuticals Inc. CASI, +3.63% were up 10% in premarket trading on Friday after the company said China will allow a Phase 1 clinical trial evaluating a multiple myeloma drug develope...

11 months ago - Market Watch

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

~ NMPA approved CB-5339 CTA for Multiple Myeloma indication ~ ~ Expected enrollment to begin in 2023 ~ ROCKVILLE, Md. and BEIJING , Jan. 6, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CAS...

11 months ago - PRNewsWire

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

ROCKVILLE, Md. and BEIJING , Dec. 15, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

1 year ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

ROCKVILLE, Md. and BEIJIN, Nov. 14, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...

1 year ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

ROCKVILLE, Md. and BEIJING , Sept.

1 year ago - PRNewsWire

ALJ Regional Hldgs (NASDAQ:ALJJ), CASI Pharmaceuticals (NASDAQ:CASI) – $2.2 Million Bet On Terns Pharmaceuticals? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: LDITERN
1 year ago - Benzinga

CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Other symbols: HCWBHSDT
1 year ago - Benzinga

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS

ROCKVILLE, Md. and BEIJING , Aug. 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

1 year ago - PRNewsWire

CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022

ROCKVILLE, Md. and BEIJING , Aug. 5, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics ...

1 year ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES ITS PARTNER, PRECISION AUTOIMMUNE THERAPEUTICS CO., LTD HAS COMPLETED FIRST-ROUND FINANCING OF $21 MILLION

~ Precision Autoimmune Therapeutics (PAT) Announced the completion of first-round financing of the equivalent of approximately US $21 million ~ ~ CASI holds 15% equity stake in PAT ~ ~ PAT will pay CA...

1 year ago - PRNewsWire

CASI Pharmaceuticals stock falls after reverse split takes effect

Shares of CASI Pharmaceuticals Inc. CASI, +18.01% are actually falling in premarket trading Thursday, as a 1-for-10 reverse stock split took effect. While some quote services may still be showing a bi...

1 year ago - Market Watch

CASI PHARMACEUTICALS ANNOUNCES REVERSE STOCK SPLIT

ROCKVILLE, Md. and BEIJING , May 26, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics ...

1 year ago - PRNewsWire

CASI PHARMACEUTICALS ENTERES INTO SUBLICENSE AGREEMENT WITH TIANSHI PHARMACEUTICALS FOR ANTI-CD38 MONOCLONAL ANTIBODY (MAB) CID-103 IN AUTOIMMUNE FIELD

~ CASI to receive upfront payment of $10 million in two instalments ~ ~ CASI through its wholly-owned PRC subsidiary, will hold 15% equity of TIANSHI ~ ROCKVILLE, Md. and BEIJING, May 24, 2022 /PRNews...

1 year ago - PRNewsWire

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS

ROCKVILLE, Md. and BEIJING , May 12, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics ...

1 year ago - PRNewsWire